Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35483 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Wunan Mi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Organoids, Drug Resistance, Neoplasm, Bile Duct Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cost Action Precision-BTC-Network, Dutch Society for Gastroenterology, Dutch Cancer Society.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a rare but devastating liver cancer which is commonly diagnosed at a late stage and often resistant to chemotherapy. Bcl‐2 family members, which control apoptotic cell death, are known to be involved in the chemoresistance of some cancer types. This study investigated the role of Bcl‐2 family members in the chemoresistance of cholangiocarcinoma organoids (CCAOs) in both undifferentiated and matured branching phenotypes (BRCCAOs). Patient‐derived CCAOs and BRCCAOs were cultured to assess chemoresistance to an FDA‐approved anticancer drug panel by testing cell viability using ATP quantification and apoptotic cell death by cleaved caspase 3 staining. More specifically, sensitivity to the first‐line drug gemcitabine was tested in combination with Bcl‐2 family inhibitors or activators. We found that in gemcitabine‐resistant CCAOs, inhibition of Bcl‐xl could overcome gemcitabine resistance and induce apoptotic cell death. Although inhibition of Mcl‐1 or activation of Bax induced spontaneous cell death, this could not overcome gemcitabine resistance. The BRCCAOs, which mimic tumor architecture better than CCAOs, show broader chemoresistance to anticancer drugs. Of note, in the resistant BRCCAOs, Bcl‐xl inhibition could restore gemcitabine sensitivity. In conclusion, this study shows that targeting Bcl‐xl can overcome chemoresistance to gemcitabine in CCA organoids. CCAOs and BRCCAOs provide good preclinical models for testing new drug combinations and assessing personalized therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands.
- Department of Organ Transplantation, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
ORCID-Profile: Wunan Mi, Luc J W van der Laan, Monique M A Verstegen
Förderung
- Cost Action Precision-BTC-Network
- Dutch Society for Gastroenterology
- Dutch Cancer Society
- Erasmus MC Human Disease Model Award 2018
- Dutch Research Council
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Mi, W., van Tienderen, G. S., Shi, S., Broeders, A., Monfils, K., Roest, H. P., van der Laan, L. J. W., & Verstegen, M. M. A. (2025). Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids. International Journal of Cancer. https://doi.org/10.1002/ijc.35483
Vancouver
Mi W, van Tienderen GS, Shi S, Broeders A, Monfils K, Roest HP, et al. Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids. International Journal of Cancer. 2025. doi:10.1002/ijc.35483
BibTeX
@article{Mi2025,
author = {Mi, Wunan and van Tienderen, Gilles S and Shi, Shaojun and Broeders, Amy and Monfils, Kathryn and Roest, Henk P and van der Laan, Luc J W and Verstegen, Monique M A},
title = {Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35483}
}
EUVIMED